CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Telix Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Telix Pharmaceuticals Ltd
55 Flemington Road, North Melbourne
Phone: +61 390933855p:+61 390933855 MELBOURNE, VIC  3051  Australia Ticker: TLXTLX
Business Summary
Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer ChristianBehrenbruch
Non-Executive Independent Chairman of the Board H. KevinMccann 9/17/2017 9/17/2017
Chief Financial Officer DouglasCubbin
16 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Artms, Inc. 8575 Commerce Ct Burnaby BC Canada
George B. Wittmer Associates Inc. 625 Oak Street Green Cove Springs FL United States
IsoTherapeutics Group, LLC 1004 S Velasco St Angleton TX United States
Qsam Biosciences Inc 9442 CAPITAL OF TEXAS HWY N AUSTIN TX United States

Business Names
Business Name
Artms, Inc.
Atlab Pharma SAS
George B. Wittmer Associates Inc.
IsoTherapeutics Group, LLC
Qsam Biosciences Inc
TLX

General Information
Number of Employees: 234 (As of 12/31/2022)
Outstanding Shares: 334,232,000 (As of 6/30/2024)
Shareholders: 12,342
Stock Exchange: ASX
Email Address: info@telixpharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024